Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2017
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570682/
https://ncbi.nlm.nih.gov/pubmed/28637662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-785246
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars